Actavia Life Sciences, Inc. (RASP)

Actavia Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Net Income	-0.41	-4.44	-0.69	-0.88	-5.35	-0.94
Depreciation & Amortization	-	-	-	0	0	0
Other Amortization	0.03	0.18	0.89	0.55	-	-
Asset Writedown & Restructuring Costs	-	-	-	-	4.87	-
Stock-Based Compensation	-	3.86	-	0.04	0.13	0.37
Other Operating Activities	0.03	0.02	-0.58	0.12	0.04	0.02
Change in Accounts Receivable	-	-	-	0	0.01	0.22
Change in Accounts Payable	0.04	0.11	-0.01	-0.12	0.05	0.17
Change in Other Net Operating Assets	0.24	0.26	0.09	-0	-0.01	0.06
Operating Cash Flow	-0.07	-0.01	-0.31	-0.29	-0.25	-0.09
Short-Term Debt Issued	-	0.11	0.41	0.29	0.22	0.1
Total Debt Issued	0.1	0.11	0.41	0.29	0.22	0.1
Short-Term Debt Repaid	-	-0.07	-0.07	-	-	-
Total Debt Repaid	-0.03	-0.07	-0.07	-	-	-
Net Debt Issued (Repaid)	0.07	0.04	0.34	0.29	0.22	0.1
Financing Cash Flow	0.07	0.04	0.34	0.29	0.22	0.1
Net Cash Flow	-0	0.04	0.03	-0	-0.04	0.01
Free Cash Flow	-0.07	-0.01	-0.31	-0.29	-0.25	-0.09
Free Cash Flow Per Share	-	-	-0.00	-0.00	-0.00	-0.00
Levered Free Cash Flow	0.01	1.57	-0.52	0.03	-0.19	0.24
Unlevered Free Cash Flow	0.01	1.52	-0.81	-0.2	-0.17	0.26
Change in Net Working Capital	-0.23	-0.31	0.57	0.09	-0.05	-0.46

Updated May 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.